Censitrac™ Compatible with ASP® STERRAD® Systems

First to Market Interface Offers End-to-End Compatibility with STERRAD® Systems in an EHR Environment

NASHVILLE, Tenn., Aug. 27, 2012 /PRNewswire/ -- Censis® Technologies, Inc., developer of Censitrac surgical instrument tracking systems, has completed research, development and implementation of full-interface compatibility with ASP® STERRAD® Systems, through the ASP Digital Transfer Interface (DTI). This equipment interface capability is made possible through Censitrac's SterilTrac module in concert with the ASP communication kits and is included in Censitrac's TrayTrac and InstrumenTrac modules annual subscription.   

"We are pleased to be the first tracking solution in the marketplace to offer full electronic interface capabilities with the ASP STERRAD® NX® and 100NX® Systems," says Randy Smith, president and chief executive officer of Censis® Technologies.  "The efficiency and patient safety implications of the interface are significant because of the elimination of the effort required to produce the manual sterilization records in a very critical area of the hospital—sterile processing for the operating room," Smith noted.

Censitrac's automated tracking for surgical instruments and trays, endoscopes, sterilization data and mobile equipment, improves infection control and provides the data for meaningful benchmarking, continuous process improvement and root cause analysis.  Censis® Technologies, Inc., has been providing leading systems for surgical instrument tracking and data management for almost ten years.

For more information about SterilTrac, TrayTrac, InstrumenTrac or Censitrac, or Censis® Technologies, Inc., visit www.censis.net.

SOURCE Censis Technologies, Inc.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.